Medication changes prior to hospitalization for obstructive lung disease: A case-crossover study

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 267-273

  Velthove, Karin J ^a,b   Leufkens, Hubert G M ^a   Schweizer, René C ^b   Van Solinge, Wouter W ^a,b   Souverein, Patrick C ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Case crossover study; Glucocorticoids; Hospitalization; Obstructive lung disease

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; MONTELUKAST; MUSCARINIC AGENT; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; DATABASES, FACTUAL; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; NETHERLANDS; YOUNG ADULT;

EID: 76149107153     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M513     Document Type: Article

References (40)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2008. www.goldcopd.org (accessed 2009 Sept 28).
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2008. www.ginasthma.org (accessed 2009 Sept 28).
3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-32. DOI 10.1183/09031936.06.00124605
4. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13. DOI 10.1183/09031936.00146306
5. Shireman TI, Heaton PC, Gay WE, Cluxton RJ, Moomaw CJ. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002;36:557-64. DOI 10.1345/aph.1A067
6. McKnight J, Scott A, Menzies D, Bourbeau J, Blais L, Lemière C. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol 2005;58:206-8. DOI 10.1016/j.jclinepi.2004.08.006
7. Blais L, Ernst P, Boivin JF, Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998;158:126-32. http://ajrccm.atsjournals.org.proxy.library.uu.nl/cgi/reprint/ 158/1/126
8. Ekberg-Aronsson M, Lofdahl K, Nilsson JA, Lofdahl CG, Nilsson PM. Hospital admission rates among men and women with symptoms of chronic bronchitis and airflow limitation corresponding to the GOLD stages of chronic obstructive pulmonary disease-a population-based study. Respir Med 2008;102:109-20. DOI 10.1016/j.rmed.2007.07.028
9. Geelhoed EA, Brameld KJ, Holman CD, Thompson PJ. Readmission and survival following hospitalization for chronic obstructive pulmonary disease: long-term trends. Intern Med J 2007;37:87-94. DOI 10.1111/j.1445-5994.2007.01240.x
10. Thomson NC, Chaudhuri R. Identification and management of adults with asthma prone to exacerbations: can we do better? BMC Pulm Med 2008;8:27. DOI 10.1186/1471-2466-8-27
11. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. Asthma exacerbations during first therapy with long acting beta 2-agonists. Pharm World Sci 1999;21:116-9. DOI 10.1023/A:1008618700934
12. Van Ganse E, Van der Linden PD, Leufkens HG, Herings RM, Vincken W, Ernst P. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8:1856-60. DOI 10.1183/09031936.95.08111856
13. Boyter AC, Steinke DT. Changes in prescribing of inhaled corticosteroids (1999-2002) in Scotland. Pharmacoepidemiol Drug Saf 2005; 14:203-9. DOI 10.1002/pds.1054
14. Simpson AJ, Matusiewicz SP, Brown PH, et al. Emergency pre-hospital management of patients admitted with acute asthma. Thorax 2000;55: 97-101. DOI 10.1136/thorax.55.2.97
15. Velthove KJ, Souverein PC, van Solinge WW, Leufkens HG, Lammers JW. Effects of corticosteroid use on readmission in obstructive lung disease. Respir Med. Epub 23 Sept 2009. DOI 10.1016/j.rmed.2009.08.014
16. Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration 2006;73:311-7. DOI 10.1159/000088092
17. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005;26:414-9. DOI 10.1183/09031936.05.00078504
18. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-timecontrol designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 1997;6(suppl 3):S51-9. DOI 10.1002/(SICI)1099-1557(199710)6:3+3.3.CO;2-J
19. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331-6. DOI 10.1016/S0140-6736(98)04087-2
20. Redelmeier DA, Tibshirani RJ. Association between cellular-telephone calls and motor vehicle collisions. N Engl J Med 1997;336:453-8. DOI 10.1056/NEJM199702133360701
21. Handoko KB, Zwart-Van Rijkom JE, Hermens WA, Souverein PC, Egberts TC. Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study. Pharmacoepidemiol Drug Saf 2007; 16:189-96. DOI 10.1002/pds.1333
22. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5. DOI 10.1001/jama.279.15.1200
23. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008;42:1017-25. Epub 1 Jul 2008. DOI 10.1345/aph.1L037
24. Leendertse AJ, Egberts AC, Stoker LJ, Van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168:1890-6. DOI 10.1001/archinternmed.2008.3
25. Peyriere H, Cassan S, Floutard E, et al. Adverse drug events associated with hospital admission. Ann Pharmacother 2003;37:5-11. DOI 10.1345/aph.1C126
26. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992;46:136- 40. DOI 10.1136/jech.46.2.136
27. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003;21:795-8. DOI 10.1183/09031936.03.00063402
28. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000;21:193-221. DOI 10.1146/annurev.publhealth.21.1.193
29. Blais L, Suissa S, Boivin JF, Ernst P. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998;53:1025-9. DOI 10.1136/thx.53.12.1025
30. Roede BM, Bresser P, Bindels PJ, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008;63:968-73. DOI 10.1136/thx.2008.095349
31. Ten Brinke A, Sterk P, Masclee A, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005;26:812-8. DOI 10.1183/09031936.05.00037905
32. Malfertheiner P, Hallerback B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). Int J Clin Pract 2005;59: 346-55. DOI 10.1111/j.1742-1241.2005.00370.x
33. Pistelli R, Lange P, Miller DL. Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity. Eur Respir J Suppl 2003;40:10s- 4s. DOI 10.1183/09031936.03.00403403
34. Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008;372:1088-99. DOI 10.1016/S0140-6736(08)61450-6
35. In't Veen J, Smits H, Hiemstra P, Zwinderman A, Sterk P, Bel E. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 1999;160:93-9. http://ajrccm.atsjournals.org/cgi/reprint/160/1/93
36. Velthove KJ, Bracke M, Souverein PC, et al. Identification of exacerbations in obstructive lung disease through biomarkers. Biomarkers 2009;14:523-8. DOI 10.1080/13547500903150763
37. Stuffken R, Heerdink ER, de Koning FHP, Souverein PC, Egberts ACG. Association between hospitalization and discontinuity of medication therapy used in the community setting in the Netherlands. Ann Pharmacother 2008;42:933-9. Epub 10 Jun 2008. DOI 10.1345/aph.1L062
38. Tovar JM, Gums JG. Monitoring pulmonary function in asthma and COPD: point-of-care testing. Ann Pharmacother 2004;38:126-33. Epub 5 Dec 2003. DOI 10.1345/aph.1D230
39. Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 2009;150:178-87. www.pubmedcentral.nih.gov/picrender.fcgi?artid = 2738592&blobtype = pdf
40. Karapinar-Carkit F, Borgsteede SD, Zoer J, Smit HJ, Egberts ACG, van den Bemt PMLA. Effect of medication reconciliation with and without patient counseling on the number of pharmaceutical interventions among patients discharged from the hospital. Ann Pharmacother 2009;43:1001-10. Epub 2 Jun 2009. DOI 10.1345/aph.1L597